StockData
GT Biopharma, Inc. logo

GT Biopharma, Inc. (GTBP) stock

GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30
$3.18−0.35 (-10.04%)

Close on Nov 17, 2026Market cap $143.45MP/E –Yield –

GT Biopharma r&d expenses

Research and development expenses are spending on new products and technology.

GT Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $3.48M, down 26.0% year over year. For fiscal 2025 it was $3.47M, down 40.1% from the year before. Over ten years it grew 13.3% a year on average. The highest annual figure on record is $9.59M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.47M-40.1%
FY2024Dec 31, 2024$5.80M-10.3%
FY2023Dec 31, 2023$6.47M-26.6%
FY2022Dec 31, 2022$8.81M-8.1%
FY2021Dec 31, 2021$9.59M+1877.5%
FY2020Dec 31, 2020$485.00K-70.9%
FY2019Dec 31, 2019$1.67M-81.6%
FY2018Dec 31, 2018$9.07M+749.0%
FY2017Dec 31, 2017$1.07M+9.5%
FY2016Dec 31, 2016$975.00K-2.5%
FY2015Dec 31, 2015$1.00M–
FY2014Dec 31, 2014$0–
FY2013Dec 31, 2013$0–
FY2012Dec 31, 2012$0-100.0%
FY2011Dec 31, 2011$17.00K-90.5%
FY2010Dec 31, 2010$179.00K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.06M+190.6%
Q1 FY2026Mar 31, 2026$413.00K-62.4%
Q4 FY2025Dec 31, 2025$1.38M-28.7%
Q3 FY2025Sep 30, 2025$634.00K-51.5%
Q2 FY2025Jun 30, 2025$363.00K-79.7%
Q1 FY2025Mar 31, 2025$1.10M+41.4%
Q4 FY2024Dec 31, 2024$1.93M+42.2%
Q3 FY2024Sep 30, 2024$1.31M-4.2%
Q2 FY2024Jun 30, 2024$1.78M-14.8%
Q1 FY2024Mar 31, 2024$777.00K-52.9%
Q4 FY2023Dec 31, 2023$1.36M-52.3%
Q3 FY2023Sep 30, 2023$1.36M-50.3%
Q2 FY2023Jun 30, 2023$2.10M+83.9%
Q1 FY2023Mar 31, 2023$1.65M-20.9%
Q4 FY2022Dec 31, 2022$2.84M-54.9%
Q3 FY2022Sep 30, 2022$2.74M+172.1%
Q2 FY2022Jun 30, 2022$1.14M+78.2%
Q1 FY2022Mar 31, 2022$2.09M+27.3%
Q4 FY2021Dec 31, 2021$6.30M+2605.6%
Q3 FY2021Sep 30, 2021$1.01M+1100.0%
Q2 FY2021Jun 30, 2021$639.00K+5225.0%
Q1 FY2021Mar 31, 2021$1.64M+406.2%
Q4 FY2020Dec 31, 2020$233.00K+2812.5%
Q3 FY2020Sep 30, 2020$84.00K-87.5%
Q2 FY2020Jun 30, 2020$12.00K-92.2%
Q1 FY2020Mar 31, 2020$324.00K-61.2%
Q4 FY2019Dec 31, 2019$8.00K-99.4%
Q3 FY2019Sep 30, 2019$671.00K-39.6%
Q2 FY2019Jun 30, 2019$154.00K-95.3%
Q1 FY2019Mar 31, 2019$834.00K-76.0%
Q4 FY2018Dec 31, 2018$1.23M+684.7%
Q3 FY2018Sep 30, 2018$1.11M+111.2%
Q2 FY2018Jun 30, 2018$3.25M+1249.0%
Q1 FY2018Mar 31, 2018$3.47M+2311.8%
Q4 FY2017Dec 31, 2017$157.00K-37.2%
Q3 FY2017Sep 30, 2017$526.00K+110.4%
Q2 FY2017Jun 30, 2017$241.00K–
Q1 FY2017Mar 31, 2017$144.00K–
Q4 FY2016Dec 31, 2016$250.00K–
Q3 FY2016Sep 30, 2016$250.00K–

More GT Biopharma figures

See a number that looks wrong?